14.40
0.45 (3.23%)
| Previous Close | 13.95 |
| Open | 13.89 |
| Volume | 1,260,802 |
| Avg. Volume (3M) | 829,673 |
| Market Cap | 1,218,766,976 |
| Price / Sales | 67.42 |
| Price / Book | 10.89 |
| 52 Weeks Range | |
| Earnings Date | 11 Mar 2025 - 17 Mar 2025 |
| Operating Margin (TTM) | -743.29% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | -23.50% |
| Total Debt/Equity (MRQ) | 141.69% |
| Current Ratio (MRQ) | 6.08 |
| Operating Cash Flow (TTM) | -75.07 M |
| Levered Free Cash Flow (TTM) | -70.25 M |
| Return on Assets (TTM) | -40.69% |
| Return on Equity (TTM) | -181.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Liquidia Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 19.49% |
| % Held by Institutions | 54.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caligan Partners Lp | 30 Sep 2024 | 8,118,592 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (HC Wainwright & Co., 101.39%) | Buy |
| Median | 24.00 (66.67%) | |
| Low | 19.00 (Needham, 31.94%) | Buy |
| Average | 24.00 (66.67%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 11.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 09 Jan 2025 | 19.00 (31.94%) | Buy | 12.46 |
| 14 Nov 2024 | 19.00 (31.94%) | Buy | 10.03 | |
| HC Wainwright & Co. | 14 Nov 2024 | 29.00 (101.39%) | Buy | 10.03 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 14.01 | -445 | -6,234 |
| Aggregate Net Quantity | -445 | |||
| Aggregate Net Value ($) | -6,234 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.01 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ADAIR JASON | Officer | 27 Jan 2025 | Automatic sell (-) | 445 | 14.01 | 6,234 |
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference |
| 13 Nov 2024 | Announcement | Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 12 Nov 2024 | Announcement | Liquidia to Present at the Stifel 2024 Healthcare Conference |
| 06 Nov 2024 | Announcement | Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |